Clinical Trial Update: A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma [Phase 2]

View source ↗

Summary

A Phase 2 study is planned to evaluate the efficacy and safety of Frevecitinib (KN-002) in patients with severe asthma, with patient recruitment not yet started…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Frevecitinib (KN-002) (Frevecitinib)

Snippet

Sponsor: Kinaset Therapeutics Inc | Conditions: Severe Asthma | Phase 2 | Status: NOT_YET_RECRUITING